![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Primaquine sensitivity, also called glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is an inborn error of metabolism. Individuals who inherit this deficiency may experience an acute hemolytic episode after ingestion of certain drugs and some vegetable food products (Brewer, Tarlov and Alving, 1959). There are about 40 drugs which can produce this effect and some of them, such as aspirin, are in very common use. G-6-PD deficiency has been reported in Jews (Szeinberg and Sheba, 1959). Iranians (Walker and Bowman, 1959). American Negroes and Africans (Motulsky, 1960). Greeks (Leda and Kattamis, 1961) and Indians (Kate. Mukherjee, Malhotra, Phadke, Mutalik and Sainari, 1978). G-6-PD activity has also been investigated in various diseases as various cancers (Sonka, Vitková, Gregorová. Tomosová, Hilgertová and Stás, 1973) malaria (Martin, Miller. Alling, Okoye, Esan, Osunkoya and Dean, 1979) and sickle cell anemia (Heller, Best, Nelson and Becktel, 1979). The purpose of this investigation was to investigate primaquine sensitivity in vitro in institutionalized persons with Down’s Syndrome who in general are quite heavily medicated.